The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Over the last 50 years, evidence for central involvement of glutamatergic neurotransmission in the pathophysiology of schizophrenia has accumulated. Recent advances in neuroimaging technology now allow several components of glutamatergic neurotransmission to be assessed in the living human brain. Positron emission tomography (PET) or single photon emission tomography (SPET) in combination with select radiotracers allows visualization of glutamatergic receptors in vivo, and magnetic resonance (MR) - based techniques allow mapping of the effects of glutamatergic agents on regional brain activation, and the measurement of regional glutamate concentrations. These imaging studies have provided evidence for regional glutamatergic abnormalities in psychosis, and are beginning to describe both the evolution of these abnormalities over the course of the illness and their response to therapeutic intervention. In parallel, advances in small animal imaging and the development of animal models have provided a platform to explore the neuropathological consequences of glutamatergic abnormality, and the potential antipsychotic efficacy of novel compounds. The molecular diversity of the glutamatergic system has driven the design of several compounds targeting aspects of glutamatergic transmission, and clinical trials have yielded encouraging results. Here, we review the contribution of imaging studies to date in understanding glutamatergic abnormalities in psychosis, and discuss the potential of new glutamatergic compounds for treatment of the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020 · cited 2×
“[12] Harrison, P.”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“[103] Moghaddam, B.”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 5×
“Complementary to dopaminergic theories is the hypothesis that schizophrenia may arise due to abnormalities in glutamatergic neurotransmission [1-5].”
BackgroundMethodInfluentialAnis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 2×
“Electrophysiological recording studies in animals show that NMDAR antagonism increases the activity of prefrontal cortical neurons [99], and that this effect results from preferential inhibition of GABAergic interneurons by NMDAR antagonists, leading to disinhibition of pyramidal neuron activity [100].”
BackgroundPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 2×
“[203] Patil, S.”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 3×
“[173] Coyle, J.”
BackgroundSchell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832 · cited 2×
“Drugs that prolong AMPAR channel open time by positive allosteric modulation, termed AMPAkines, thereby increase NMDAR activation, and may also increase extracellular D-serine levels [192].”
Background
Cited by
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0071-9 · Cited by 352
Lobellova, V., Entlerova, M., Svojanovska, B., Hatalova, H., Prokopova, I., Petrasek, T., Vales, K., Kubik, S., Fajnerova, I., & Stuchlik, A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.03.006 · Cited by 47
Huang, Z., Davis Iv, H. H., Yue, Q., Wiebking, C., Duncan, N. W., Zhang, J., Wagner, N.-F., Wolff, A., & Northoff, G. (2015) · Human Brain Mapping · doi:10.1002/hbm.22841 · Cited by 43
Krivoy, A., Hochman, E., Sendt, K.-V., Hollander, S., Vilner, Y., Selakovic, M., Weizman, A., & Taler, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.05.040 · Cited by 33
Metadata
- Authors
- Egerton, A., & M. Stone, J.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-05-01
- Volume
- 13
- Issue
- 8
- Pages
- 1500-1512
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2039474546
- Cited by
- 49
- References
- 39
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development. https://app.cochat.ai/papers/10.2174/138920112800784961
- The paper
- Egerton, A., & M. Stone, J. (2012). The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development. Current Pharmaceutical Biotechnology. https://doi.org/10.2174/138920112800784961
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.